Amicus Therapeutics to Present at the Leerink Part
Post# of 301275
CRANBURY, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Leerink Partners 6 th Annual Global Healthcare Conference in New York, NY on Thursday, February 16, 2017 at 11 a.m. ET.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm , and will be archived for 90 days.
About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD ) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations spellegrino@amicusrx.com (609) 662-5044 Media: MWW PR Sid Dinsay sdinsay@mww.com (646) 381-9017
(0)
(0)